Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Contact us

Phone: +44 (0)1865 857240


UKPDS was a randomised, multicentre trial of glucose-lowering and antihypertensive therapies in patients with newly diagnosed type 2 diabetes. The study showed that complications of diabetes could be reduced by more intensive blood glucose and/or blood pressure control using existing treatments and dramatically changed the management of type 2 diabetes worldwide.

The UKPDS Legacy Study is an extended follow-up of UKPDS using electronic health records and other routinely collected health data.


The UKPDS Legacy Study intends to obtain updated forty-year follow-up data for the original participants of the UKPDS study by accessing electronic health record data via NHS Digital and NHS Scotland.


To investigate whether early more intensive blood glucose and/or blood pressure control is associated with:

  • A reduction in the risk of dementia
  • A reduced risk of major vascular disease in the longer term

To assess the health economic impact of early more intensive blood glucose and/or blood pressure control over a lifetime horizon


If you were a UKPDS participant, you can read the privacy notice for the UKPDS Legacy study here.

Chief investigator Rury Holman
Co-investigators William Whiteley
Alastair Gray
Jose Leal
Ruth Coleman
Sponsor University of Oxford
Funder Diabetes Trials Unit, University of Oxford
Chief Scientist’s Office, Scotland
Reference number IRAS: 249166

Latest News

Intensive blood glucose control for people with type 2 diabetes when they are first diagnosed reduces diabetic complications and prolongs life

The study, which tracked volunteers for up to 44 years, showed that the benefits of early intensive blood glucose control can persist for decades.